| DC22394 |
Elaiophylin |
Elaiophylin (Gopalamicin. |
|
| DC22182 |
Elatol |
Elatol (NSC 341593) is a specific inhibitor of ATP hydrolysis by eIF4A1 in vitro with broad activity against multiple tumor types. |
|
| DC21774 |
Eletriptan |
Eletriptan (UK 116044) is a potent, selective, and orally active 5-HT1B/1D receptor agonist. |
|
| DC7772 |
Elinogrel |
Elinogrel is a reversible P2Y12 receptor antagonist for the treatment of acute coronary syndrome and prevention of secondary thrombotic events. |
|
| DC7786 |
ELN 441958
Featured
|
ELN-441958 is a potent, neutral antagonist of B1 receptor, inhibits the binding of the B1 agonist ligand [3H]DAKD to IMR-90 cells with Ki of 0.26 nM. ELN-441958 is highly selective for B1 over B2 receptors, and >500/ 2000-fold selective for the B1 over μ/δ-opioid receptor.IC50 value: 0.26 nM (Ki)Target: B1 Receptorin vitro: ELN-441958 is a novel small molecule bradykinin B1 receptor antagonist, based on the inhibition of agonist-induced increases in intracellular calcium in native and recombinant cells. ELN-441958 does not inhibit the activation of the human bradykinin B2 receptor at concentrations up to 10 μM, showing that it is highly selective for B1 over B2 receptors. ELN-441958 also displays good selectivity for B1 over other receptors examined in a broad screening panel. It is >500-fold and >2000-fold selective for the B1 receptor over the human μ- and δ-opioid receptor, the most potent off-target activity identified. In IMR-90 cells expressing the native human B1 receptor, ELN-441958 produced a concentration-dependent antagonism of the DAKD-induced calcium mobilization with a KB of 0.12 nM. [1]in vivo: ELN-441958 is essentially completely absorbed and produces high plasma levels after oral administration in rhesus monkeys.ELN-441958 has a moderate clearance and volume of distribution in both species following i.v. administration, consistent with the high metabolic stability in rat, rhesus, and human microsomes. ELN-441958 has high oral exposure and moderate plasma half-lives in rats and rhesus monkeys. The oral availability of ELN441958 in rats was 57%. ELN-441958 dose-dependently reduced carrageenan-induced thermal hyperalgesia in a rhesus monkey tail-withdrawal model, with an ED50 3 mg/kg s.c. [1] |
|
| DC7779 |
ELND0006 |
ELND006 is a novel gamma secretase inhibitor previously under investigation for the oral treatment of Alzheimer's disease. |
|
| DC8369 |
Eltrombopag olamine
Featured
|
Eltrombopag olamine is a new, orally active thrombopoietin-receptor (c-mpl) agonist that stimulates thrombopoiesis. |
|
| DC23523 |
Elubrixin tosylate |
Elubrixin (SB-656933) is a potent, selective, competitive and reversible CXCR2 antagonist. |
|
| DC21618 |
Elubrixin |
Elubrixin (SB-656933, GSK-656933) is a potent, selective, competitive and reversible CXCR2 antagonist. |
|
| DC21465 |
EMA300 |
EMA300 (PD1 21981) is a potent, selective small molecule antagonist of angiotensin II type 2 receptor (AT2R) with >1,000-fold selectivity over AT1 receptor, produces analgesia in rodent model of neuropathic pain.. |
|
| DC8706 |
Emamectin Benzoate |
Emamectin Benzoate works as a chloride channel activator by binding gamma aminobutyric acid (GABA) receptor and glutamate-gated chloride channels disrupting nerve signals within arthropods. |
|
| DC11028 |
EMD-281014 hydrochloride |
EMD-281014 hydrochloride is a potent, highly selective 5-HT2A antagonist with Ki of 0.87 nM, displays little to no affinity for 5-HT2C receptors (Ki=557 nM), human D2 receptors and IKr channels. |
|
| DC11027 |
EMD-281014 |
EMD-281014 is a potent, highly selective 5-HT2A antagonist with Ki of 0.87 nM, displays little to no affinity for 5-HT2C receptors (Ki=557 nM), human D2 receptors and IKr channels. |
|
| DC7117 |
EMD534085 |
EMD534085 is a kinesin inhibitor currently in clinical development. |
|
| DC10314 |
Emixustat |
Emixustat, a novel visual cycle modulator, is an inhibitor of the visual cycle isomerase with an IC50 value of 4.4 nM in vitro. |
|
| DC22785 |
EML-405 |
EML-405 (EML405) is a small-molecule inhibitor of Spindlin1 (SPIN1) with Kd of 14 uM. |
|
| DC10301 |
Emodepside
Featured
|
Emodepside (PF 1022-221) is a cyclooctadepsipeptide with broad-spectrum anthelmintic activity. |
|
| DC23171 |
Empesertib(BAY 1161909)
Featured
|
Empesertib (BAY-1161909, BAY1161909) is a potent, selective Monopolar spindle 1 (Mps1/TTK) inhibitor with IC50 of 0.34 nM. |
|
| DC12273 |
EMT inhibitor-1 |
EMT inhibitor-1 is an inhibitor of of Hippo, TGF-β, and Wnt signaling pathways with antitumor activities. |
|
| DC23108 |
EN460
Featured
|
EN460 is a specific mall molecule inhibitor of endoplasmic reticulum oxidation 1 (ERO1), interacts selectively with the reduced, active form of ERO1α and prevents its reoxidation (IC50=1.9 uM). |
|
| DC20892 |
Enadoline |
Enadoline (CI 977. |
|
| DC20993 |
ENMD-1068
Featured
|
ENMD-1068 is a novel selective PAR2 antagonist without inhibitory activity against thrombin-mediated PAR3 and PAR4 signaling. |
|
| DC8778 |
Enocitabine |
Enocitabine is an anti-tumor agent and an antineoplastic. A derivative of Cytarabine. |
|
| DC20018 |
Enocyanin
Featured
|
Enocyanin is an anthocyanin extracted from grapes. Enocyanin shows inhibitory effect on the leucine aminopeptidase, acid phosphatase, γ-glutamyl transpeptidase and esterase activity. |
|
| DC4208 |
Entecavir Monohydrate
Featured
|
Entecavir hydrate belongs to the family of medicines called antivirals. |
|
| DC8881 |
Entecavir |
Entecavir is a deoxyguanosine nucleoside analogue with antiviral activity against the hepatitis B virus (HBV). |
|
| DC6909 |
Entinostat (MS-275)
Featured
|
Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM, compared with HDACs 4, 6, 8, and 10. Phase 1/2. |
|
| DC21856 |
Enviroxime |
Enviroxime (Zinviroxime. |
|
| DC20848 |
Enzaplatovir |
Enzaplatovir (BTA-585, BTA-C585) is an orally bioavailable RSV fusion protein inhibitor for the treatment of respiratory syncytial virus infections.. |
|
| DC20950 |
EOAI3402143 |
EOAI3402143 (Deubiquitinase inhibitor G9, EOAI 3402143) is a novel covalent deubiquitinase Usp9x/Usp24 inhibitor with increased aqueous solubility and greater cellular Usp9x inhibitory activity than WP1130. |
|
